Close Menu

NEW YORK – Precision oncology firm Burning Rock Biotech this week presented data at two scientific conferences supporting two products it expects to be major growth drivers in coming years.

At the annual meeting of the Association for Molecular Pathology, held virtually, researchers from the company presented a study describing the validation of its automated next-generation sequencing library prep solution Magnis BR, which was launched last year.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.